TY  - JOUR 
AU  - Blancas López-Barajas, María Isabel
AU  - Martín-Pérez, Francisco J.
AU  - Garrido Jiménez, José Manuel
AU  - Rodríguez Serrano, Fernando
PY  - 2020
UR  - http://hdl.handle.net/10481/66803
AB  - Background

Trastuzumab is a drug used in HER2-positive breast cancer that increases patient survival. Due to cardiotoxicity is the most important side effect of trastuzumab treatment, cardiac monitoring should be a priority. The purpose of this...
LA  - eng
PB  - Elsevier
KW  - Breast cancer
KW  - Trastuzumab
KW  - Cardiotoxicity
KW  - HER-2
KW  - Early diagnosis
KW  - NT-proBNP
TI  - NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients
DO  - 10.1016/j.breast.2020.09.001
ER  -